Fluicell AB (publ) ("Fluicell" or the "Company") has today entered into an exclusive and global license and development agreement with Ambusol AB (publ) ("Ambusol"), which includes the use of Fluicell's microflow platform Nexocyte, as well as the development of a new catheter technology adapted for Ambusol, for the treatment of cancer. The agreement provides Fluicell with up to SEK 142 million, divided into SEK 1.5 million in upfront payments, SEK 29 million in [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.